FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212789313> ?p ?o ?g. }

• W4212789313 endingPage "1288" @default.
• W4212789313 startingPage "1277" @default.
• W4212789313 abstract "Muscle regeneration includes proliferation and differentiation of muscle satellite cells, which involves the mammalian target of rapamycin (mTOR). We identified the C-terminal unique attached sequence motif (UNE) domain of leucyl-tRNA synthetase (LRS-UNE-L) as an mTORC1 (mTOR complex1)-activating domain that acts through Vps34 and phospholipase D1 (PLD1) when introduced in the form of a muscle-enhancing peptide.In vitro Vps34 lipid kinase assay, phosphatidylinositol 3-phosphate (PI(3)P) measurement, in vivo PLD1 assay, and western blot assay were performed in HEK293 cells to test the effect of the LRS-UNE-L on the Vps34-PLD1-mTOR pathway. Adeno-associated virus (AAV)-LRS-UNE-L was transduced in C2C12 cells in vitro, in BaCl2 -injured tibialis anterior (TA) muscles, and in 18-month-old TA muscles to analyse its effect on myogenesis, muscle regeneration, and aged muscle, respectively. The muscle-specific cell-permeable peptide M12 was fused with LRS-UNE-L and tested for cell integration in C2C12 and HEK293 cells using FACS analysis and immunocytochemistry. Finally, M12-LRS-UNE-L was introduced into BaCl2 -injured TA muscles of 15-week-old Pld1+/+ or Pld1-/- mice, and its effect was analysed by measurement of cross-sectional area of regenerating muscle fibres.The LRS-UNE-L expression restored amino acid-induced S6K1 phosphorylation in LRS knockdown cells in a RagD GTPases-independent manner (421%, P = 0.007 vs. LRS knockdown control cells). The LRS-UNE-L domain was directly bound to Vps34; this interaction was accompanied by increases in Vps34 activity (166%, P = 0.0352), PI(3)P levels (146%, P = 0.0039), and PLD1 activity (228%, P = 0.0294) compared with amino acid-treated control cells, but it did not affect autophagic flux. AAV-delivered LRS-UNE-L domain augmented S6K1 phosphorylation (174%, P = 0.0013), mRNA levels of myosin heavy chain (MHC) (122%, P = 0.0282) and insulin-like growth factor 2 (IGF2) (146%, P = 0.008), and myogenic fusion (133%, P = 0.0479) in C2C12 myotubes. AAV-LRS-UNE-L increased the size of regenerating muscle fibres in BaCl2 -injured TA muscles (124%, P = 0.0279) (n = 9-10), but it did not change the muscle fibre size of TA muscles in old mice. M12-LRS-UNE-L was preferentially delivered into C2C12 cells compared with HEK293 cells and augmented regeneration of BaCl2 -injured TA muscles in a PLD1-dependent manner (116%, P = 0.0022) (n = 6).Our results provide compelling evidence that M12-LRS-UNE-L could be a muscle-enhancing protein targeting mTOR." @default.
• W4212789313 created "2022-02-24" @default.
• W4212789313 creator A5032767655 @default.
• W4212789313 creator A5046219540 @default.
• W4212789313 creator A5052232840 @default.
• W4212789313 creator A5072259603 @default.
• W4212789313 creator A5087073169 @default.
• W4212789313 date "2022-02-17" @default.
• W4212789313 modified "2023-10-16" @default.
• W4212789313 title "Self‐transducible LRS‐UNE‐L peptide enhances muscle regeneration" @default.
• W4212789313 cites W1586159393 @default.
• W4212789313 cites W1972440687 @default.
• W4212789313 cites W1982501876 @default.
• W4212789313 cites W1990965764 @default.
• W4212789313 cites W1997642684 @default.
• W4212789313 cites W2016815316 @default.
• W4212789313 cites W2022223340 @default.
• W4212789313 cites W2046323838 @default.
• W4212789313 cites W2056664023 @default.
• W4212789313 cites W2071657693 @default.
• W4212789313 cites W2087071824 @default.
• W4212789313 cites W2087089750 @default.
• W4212789313 cites W2100534662 @default.
• W4212789313 cites W2113731866 @default.
• W4212789313 cites W2119392009 @default.
• W4212789313 cites W2124793833 @default.
• W4212789313 cites W2149451793 @default.
• W4212789313 cites W2158690941 @default.
• W4212789313 cites W2168492534 @default.
• W4212789313 cites W2170495419 @default.
• W4212789313 cites W2431575019 @default.
• W4212789313 cites W2495070040 @default.
• W4212789313 cites W2567665210 @default.
• W4212789313 cites W27555781 @default.
• W4212789313 cites W2757036155 @default.
• W4212789313 cites W2806012625 @default.
• W4212789313 cites W2932576322 @default.
• W4212789313 cites W2937226397 @default.
• W4212789313 cites W2944096460 @default.
• W4212789313 cites W3090434172 @default.
• W4212789313 cites W3092771387 @default.
• W4212789313 cites W4200379278 @default.
• W4212789313 cites W4212789313 @default.
• W4212789313 doi "https://doi.org/10.1002/jcsm.12947" @default.
• W4212789313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35178893" @default.
• W4212789313 hasPublicationYear "2022" @default.
• W4212789313 type Work @default.
• W4212789313 citedByCount "4" @default.
• W4212789313 countsByYear W42127893132022 @default.
• W4212789313 countsByYear W42127893132023 @default.
• W4212789313 crossrefType "journal-article" @default.
• W4212789313 hasAuthorship W4212789313A5032767655 @default.
• W4212789313 hasAuthorship W4212789313A5046219540 @default.
• W4212789313 hasAuthorship W4212789313A5052232840 @default.
• W4212789313 hasAuthorship W4212789313A5072259603 @default.
• W4212789313 hasAuthorship W4212789313A5087073169 @default.
• W4212789313 hasBestOaLocation W42127893133 @default.
• W4212789313 hasConcept C104317684 @default.
• W4212789313 hasConcept C105702510 @default.
• W4212789313 hasConcept C11960822 @default.
• W4212789313 hasConcept C153911025 @default.
• W4212789313 hasConcept C173396325 @default.
• W4212789313 hasConcept C185592680 @default.
• W4212789313 hasConcept C207200792 @default.
• W4212789313 hasConcept C2776415932 @default.
• W4212789313 hasConcept C2779959927 @default.
• W4212789313 hasConcept C2780610907 @default.
• W4212789313 hasConcept C3763915 @default.
• W4212789313 hasConcept C54355233 @default.
• W4212789313 hasConcept C55493867 @default.
• W4212789313 hasConcept C60278653 @default.
• W4212789313 hasConcept C62478195 @default.
• W4212789313 hasConcept C81885089 @default.
• W4212789313 hasConcept C86554907 @default.
• W4212789313 hasConcept C86803240 @default.
• W4212789313 hasConcept C95444343 @default.
• W4212789313 hasConceptScore W4212789313C104317684 @default.
• W4212789313 hasConceptScore W4212789313C105702510 @default.
• W4212789313 hasConceptScore W4212789313C11960822 @default.
• W4212789313 hasConceptScore W4212789313C153911025 @default.
• W4212789313 hasConceptScore W4212789313C173396325 @default.
• W4212789313 hasConceptScore W4212789313C185592680 @default.
• W4212789313 hasConceptScore W4212789313C207200792 @default.
• W4212789313 hasConceptScore W4212789313C2776415932 @default.
• W4212789313 hasConceptScore W4212789313C2779959927 @default.
• W4212789313 hasConceptScore W4212789313C2780610907 @default.
• W4212789313 hasConceptScore W4212789313C3763915 @default.
• W4212789313 hasConceptScore W4212789313C54355233 @default.
• W4212789313 hasConceptScore W4212789313C55493867 @default.
• W4212789313 hasConceptScore W4212789313C60278653 @default.
• W4212789313 hasConceptScore W4212789313C62478195 @default.
• W4212789313 hasConceptScore W4212789313C81885089 @default.
• W4212789313 hasConceptScore W4212789313C86554907 @default.
• W4212789313 hasConceptScore W4212789313C86803240 @default.
• W4212789313 hasConceptScore W4212789313C95444343 @default.
• W4212789313 hasFunder F4320322107 @default.
• W4212789313 hasFunder F4320322120 @default.
• W4212789313 hasIssue "2" @default.

• next